This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases, Other  • Oncology  • Lung Cancer  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:1963-1964.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Diego—For the cancer that claims more lives than any other, the past year was noteworthy in terms of both research and therapy. Although more than 150 000 people in the United States die of lung cancer each year, new studies are making strides toward improving tumor response and prolonging survival for patients. At the American Association for Cancer Research’s recent conference, "Molecular Pathogenesis of Lung Cancer: Opportunities for Translation to the Clinic," researchers discussed the latest findings and ongoing studies.

Therapies that target the epidermal growth factor receptor (EGFR), a protein mutated in some cancer patients, have dominated the headlines for lung cancer clinical trials recently. The drug erlotinib, an EGFR inhibitor, was approved last November for the treatment of advanced or metastatic refractory non–small-cell lung cancer following a phase 3 trial with 731 patients that demonstrated that those taking the drug had a modest survival . . . [Full Text of this Article]

TROUBLE WITH TARGETING